AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Applied DNA Sciences Changes Ticker Symbol to BNBX Reflecting Digital Asset Strategy
ByAinvest
Monday, Oct 6, 2025 8:05 am ET1min read
Applied DNA Sciences is changing its ticker symbol from "APDN" to "BNBX" on the Nasdaq Capital Market on October 7, 2025. The new ticker symbol reflects the company's strategic commitment to a BNB-based treasury strategy, aiming to optimize yield generation and token accumulation within the Binance ecosystem. The company plans to integrate actively managed decentralized finance protocols and Binance ecosystem-specific strategies to enhance capital efficiency, liquidity resilience, and exposure to digital asset upside. No action is required from stockholders, and the common stock will continue to be listed on Nasdaq with an unchanged CUSIP number.
Applied DNA Sciences, Inc. (NASDAQ: APDN) has announced a significant change in its ticker symbol. Effective October 7, 2025, the company's ticker on the Nasdaq Capital Market will change from "APDN" to "BNBX" [1]. This change underscores the company's strategic commitment to a Binance Coin (BNB)-based treasury strategy, aiming to optimize yield generation and token accumulation within the Binance ecosystem.The new ticker symbol "BNBX" reflects the company's strategic shift towards integrating actively managed decentralized finance (DeFi) protocols and Binance ecosystem-specific strategies. These efforts are designed to enhance capital efficiency, liquidity resilience, and exposure to digital asset upside. The company plans to deploy a differentiated approach to treasury management, leveraging the Binance ecosystem to maximize the benefits of its digital asset holdings.
No action is required from the company's stockholders regarding the ticker symbol change. The common stock will continue to be listed on Nasdaq, and the CUSIP number will remain unchanged. Investors are advised to update their records to reflect the new ticker symbol.
Applied DNA Sciences is a biotechnology company that executes a yield-focused BNB digital asset treasury strategy while also commercializing proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet